China Gastroesophageal Reflux Disease Therapeutics Market Size & Outlook
China gastroesophageal reflux disease therapeutics market, 2018-2030 (US$M)
Related Markets
China gastroesophageal reflux disease therapeutics market highlights
- The China gastroesophageal reflux disease therapeutics market generated a revenue of USD 338.7 million in 2023 and is expected to reach USD 468.5 million by 2030.
- The China market is expected to grow at a CAGR of 4.7% from 2024 to 2030.
- In terms of segment, antacids was the largest revenue generating drug type in 2023.
- H2 Receptor Blockers is the most lucrative drug type segment registering the fastest growth during the forecast period.
Gastroesophageal reflux disease therapeutics market data book summary
| Market revenue in 2023 | USD 338.7 million |
| Market revenue in 2030 | USD 468.5 million |
| Growth rate | 4.7% (CAGR from 2023 to 2030) |
| Largest segment | Antacids |
| Fastest growing segment | H2 Receptor Blockers |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic agents |
| Key market players worldwide | AstraZeneca PLC, Eisai Co Ltd, GSK PLC, Takeda Pharmaceutical Co Ltd, Ironwood Pharmaceuticals Inc Class A, Johnson & Johnson, Phathom Pharmaceuticals Inc Ordinary shares |
Other key industry trends
- In terms of revenue, China accounted for 6.4% of the global gastroesophageal reflux disease therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China gastroesophageal reflux disease therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 468.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Gastroesophageal Reflux Disease Therapeutics Market Scope
Gastroesophageal Reflux Disease Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China gastroesophageal reflux disease therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastroesophageal reflux disease therapeutics market will help companies and investors design strategic landscapes.
Antacids was the largest segment with a revenue share of 56.63% in 2023. Horizon Databook has segmented the China gastroesophageal reflux disease therapeutics market based on antacids, h2 receptor blockers, proton pump inhibitors (ppis), pro-kinetic agents covering the revenue growth of each sub-segment from 2018 to 2030.
The prevalence rate of GERD in China is around 6.2%. According to some studies, long working hours and stressed lifestyles resulted in higher incidence of acid reflux. The prevalence of GERD in China is comparatively lower than the European countries.
Reasons to subscribe to China gastroesophageal reflux disease therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China gastroesophageal reflux disease therapeutics market databook
-
Our clientele includes a mix of gastroesophageal reflux disease therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China gastroesophageal reflux disease therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into China gastroesophageal reflux disease therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China gastroesophageal reflux disease therapeutics market outlook size, by drug type, 2018-2030 (US$M)
China Gastroesophageal Reflux Disease Therapeutics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
